PRME News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PR

Mkt Cap

$628.5M

Volume

3.83M

Next Earnings

November 6th

Loading chart

PR

PRMEPrime Medicine, Inc. Common Stock

PRME

Pay with—

Available Balance0.00

PR

Mkt Cap

$654.8M

Volume

3.83M

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyPrime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.Zacks Investment Research · Oct 12, 2026

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseasePrime Medicine announced the first patient dosing in its Phase 1/2 clinical trial of PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. The FDA granted Rare Pediatric Disease designation to PM577, and the company expects initial clinical data in 2027. PM577a is designed as a one-time curative therapy targeting the most prevalent Wilson disease-causing mutation in North America and Europe.GlobeNewswire Inc. · Oct 5, 2026

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Therapeutix is recommended as the better choice for average investors in 2026 due to its more advanced development stage and clearer investment thesis, though both remain high-risk biotech plays.The Motley Fool · Jun 15, 2026

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepThe regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.Benzinga · Apr 1, 2026

Prime Medicine to Participate in Upcoming Investor ConferencesPrime Medicine announced that company management will participate in three upcoming healthcare and biotech conferences in March 2026, including fireside chats at the TD Cowen Health Care Conference and Citizens Life Sciences Conference, as well as 1x1 meetings at the Jefferies Biotech on the Beach Summit. Live webcasts of the fireside chats will be available on the company's website.GlobeNewswire Inc. · Feb 25, 2026

Gene Therapy: 5 Biotech Stocks Chasing the $36B PrizeThe gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.Benzinga · Jan 2, 2026

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseasePrime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.GlobeNewswire Inc. · Dec 7, 2025

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesPrime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.GlobeNewswire Inc. · Nov 7, 2025

PRME Revenue Misses by 73%Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.The Motley Fool · Aug 7, 2025

Prime Medicine Announces Pricing of Public OfferingPrime Medicine is conducting a public offering of 38 million shares at $3.30 per share, expecting to raise approximately $125.4 million. The Cystic Fibrosis Foundation will purchase 1,818,181 shares, and the offering is expected to close on August 1, 2025.GlobeNewswire Inc. · Jul 31, 2025

to start trading

PR

PRMEPrime Medicine, Inc. Common Stock

PRME

Pay with—

Available Balance0.00

Your PositionYou don't own any PRME yet.

Related Tickers

Earnings